Victory Capital Management Inc. boosted its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 44.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,211 shares of the biotechnology company’s stock after buying an additional 18,190 shares during the quarter. Victory Capital Management Inc. owned approximately 0.22% of Aclaris Therapeutics worth $1,528,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ACRS. Eagle Asset Management Inc. boosted its stake in Aclaris Therapeutics by 287.3% in the 2nd quarter. Eagle Asset Management Inc. now owns 1,357,973 shares of the biotechnology company’s stock valued at $36,828,000 after buying an additional 1,007,343 shares in the last quarter. Franklin Resources Inc. boosted its stake in Aclaris Therapeutics by 55.4% in the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after buying an additional 697,104 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Aclaris Therapeutics by 79.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,249,254 shares of the biotechnology company’s stock valued at $33,880,000 after buying an additional 553,752 shares in the last quarter. FMR LLC boosted its stake in Aclaris Therapeutics by 14.6% in the 2nd quarter. FMR LLC now owns 1,896,206 shares of the biotechnology company’s stock valued at $51,425,000 after buying an additional 242,269 shares in the last quarter. Finally, Nexthera Capital LP boosted its stake in Aclaris Therapeutics by 204.9% in the 2nd quarter. Nexthera Capital LP now owns 340,000 shares of the biotechnology company’s stock valued at $9,221,000 after buying an additional 228,500 shares in the last quarter. 85.22% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Aclaris Therapeutics, Inc. (ACRS) Position Increased by Victory Capital Management Inc.” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/aclaris-therapeutics-inc-acrs-position-increased-by-victory-capital-management-inc/1719228.html.

Several brokerages have issued reports on ACRS. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. BidaskClub downgraded Aclaris Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. JMP Securities reiterated an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Aclaris Therapeutics in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $39.20.

Aclaris Therapeutics, Inc. (ACRS) opened at $22.69 on Wednesday. Aclaris Therapeutics, Inc. has a 52-week low of $21.47 and a 52-week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.23. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $2.00 million. equities analysts expect that Aclaris Therapeutics, Inc. will post -2.59 EPS for the current fiscal year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.